In the United States, the FDA grants Fast Track designation to drugs that treat rare and serious conditions or fill unmet needs. The designation helps to facilitate and expedite the…
The American Society of Hematology (ASH) held its 64th Annual Meeting in December 2022, during which time a variety of medical stakeholders discussed issues, trends, and research in the…
According to a story from ca.sports.yahoo.com, the biotechnology company Galecto, Inc. has announced encouraging findings from an intermediate assessment of its phase 2a clinical trial. This trial is evaluating the…
In a press release on the company website, biopharmaceutical company AbbVie shared that preliminary data was available regarding navitoclax, an investigational therapy, for individuals with primary myelofibrosis. The data…
In a Case-Based Roundtable for Targeted Oncology, Dr. Haris Ali, an associate professor with the City of Hope Department of Hematology and Hematopoietic Stem Cell Transplantation, discussed a case of…
On February 8, 2021, global biopharmaceutical company Bristol Myers Squibb shared that the European Commission (EC) approved a Marketing Authorization Application (MAA) for Inrebic (fedratinib). For around 10 years, there…
According to a story from Medpage Today, the Society of Hematologic Oncology recently held its virtual meeting on September 9-12. During the event, Dr. Srdan Verstovsek of the MD Anderson…
Myeloproliferative neoplasm (MPN) International Awareness Day is on September 10th. This year, there will be a live streaming event to help bring awareness to this condition, instead of an in-person…
.jpg)
Myelofibrosis (MF) comes under the heading of rare cancer. A recent article in Newswise, University of Utah, describes the disease as the failure of bone marrow to produce normal…
A new clinical trial, which can be found here at clinicaltrials.gov, is slated to begin and is currently recruiting patients. In this trial, the investigational drug pacritinib will be tested…
There's an old fable that reminds me, in a way, of primary myelofibrosis, or PMF: A shepherd is in the desert with his camel, and as night approaches, he pitches…
Primary myelofibrosis is one in a group of rare diseases called myeloproliferative neoplasms, or MPNs. It is characterized by an overproduction of one of the three components of blood: red cells,…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
